Tirzepatide Zepbound® – Injectable

(Commercial Product)

Available Dosage Strengths

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Tirzepatide (Zepbound^®) Injection (Commercial Product by Eli Lilly Company)

Tirzepatide Description^1-4

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a once-weekly subcutaneous injection indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or who are overweight.

Mechanism of Action

Mechanism of Action^1-3

Tirzepatide exerts its effects through dual incretin receptor agonism, targeting both:

GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor:

Enhances insulin secretion
Reduces glucagon secretion
Promotes lipid metabolism and may contribute to weight loss

GLP-1 (Glucagon-Like Peptide-1) Receptor:

Delays gastric emptying
Reduces appetite
Stimulates insulin release in a glucose-dependent manner
Inhibits glucagon release during hyperglycemia

Adverse Reactions

Adverse Reactions^1-4

Most adverse reactions are gastrointestinal in nature and dose-dependent:

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite, abdominal pain
Headache, dizziness, and injection site reactions

Contraindications & Precautions

Contraindications & Precautions^1-4

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
History of serious hypersensitivity to tirzepatide or any component of the formulation
Nonketotic hyperglycinemia (NKH) or other genetic disorders preventing absorption of amino acids.

Precautions:

Pancreatitis risk: Monitor patients for signs/symptoms (serious abdominal pain)
Severe gastrointestinal disease: Use with caution; only if benefit outweighs potential risk.
Acute kidney injury: Especially in those with dehydration, vomiting, or diarrhea.
Diabetic retinopathy: Rapid improvement in glucose may worsen retinopathy.
Use with insulin or secretagogues: Dose adjustment may be necessary to reduce hypoglycemia risk.
Pregnancy & Lactation: No adequate data; not recommended. Use only if benefit outweighs potential risk. Discontinue at least 1 month prior to a planned pregnancy due to long half-life

Storage

Store refrigerated at 36°F to 46°F (2°C – 8°C). Discard within 28 days of puncture or according to the beyond-use date. Do not freeze. Keep out of reach of children.

References

Clinical Pharmacology powered by Elsevier (ClinicalKey) – Tirzepatide Monograph. https://www.clinicalkey.com Accessed February 5, 2026.
FDA Prescribing Information – Zepbound® (tirzepatide): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf Lilly USA, LLC, Indianapolis, IN 46285, USA March 2023. Accessed February 5, 2026
Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM. 2022; 387(3):205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 
Drucker DJ. “Mechanisms of Action and Therapeutic Application of GLP-1 and GIP.” Cell Metabolism. 2018. https://doi.org/10.1016/j.cmet.2018.06.015

Disclaimer

Wells Pharmacy Network is a 503B-registered outsourcing facility that compounds sterile medications in accordance with current good manufacturing practices (cGMP). Certain FDA-approved products referenced on this site are distributed separately from compounded preparations and are not manufactured by Wells Pharmacy Network. Actual products in stock at time of dispensing may vary due to supply chain variability.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.